¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"prothrombin activator"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® prothrombin time ÇÑ±Û ÇÁ·ÎÆ®·Òºó½Ã°£
¼³¸í   
  ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î Æ¯Á¤Çϴ °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • activator
    1. Ȱ¼ºÁ¦ 2. Åα³Á¤ÀåÄ¡
  • activator reaction
    Ȱ¼ºÁ¦¹ÝÀÀ
  • catabolite (gene) activator protein
    ºÐÇØ´ë»ç»ê¹°(À¯ÀüÀÚ)Ȱ¼º´Ü¹éÁú
  • catabolite activator protein
    ºÐÇØ´ë»ç»ê¹°È°¼º´Ü¹éÁú
  • polyclonal activator
    ´ÙŬ·ÐȰ¼ºÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activator
    1. Ȱ¼ºÁ¦, 2. Åα³Á¤ÀåÄ¡
  • tissue plasminogen activator
    Á¶Á÷Çö󽺹̳ë°ÕȰ¼ºÁ¦
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
  • activator
    Ȱ¼ºÁ¦, Åα³Á¤ÀåÄ¡
  • activator reaction
    Ȱ¼ºÁ¦¹ÝÀÀ
  • polyclonal activator
    ´ÙŬ·ÐȰ¼ºÁ¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • SPCA= serum prothrombin conversion a
    Ç÷ûÇÁ·ÎÆ®·ÒºóÀüÈ­ÃËÁø¼Ò.
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin complex concentrates
    ÇÁ·ÎÆ®·Òºó º¹ÇÕ ³óÃà(¹°)
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó ½Ã°£
  • activator
    Ȱ¼ºÈ­Á¦(üÀàõûúð¥), ºÎȰü(Ý·üÀô÷). Ä¡°ú,»ýÈ­±â´ÉÀû ¾Ç±³Á¤ÀåÄ¡(ѦÒöîÜäÉÎìïáíûöÇ).
  • activator
    Ȱ¼ºÁ¦(üÀàõð¥), ºÎȰü(Ý·üÀô÷). [Ä¡°ú,»ýÈ­]±â´ÉÀû ¾Ç±³Á¤ÀåÄ¡(ѦÒöîÜäÉÎìïáíûöÇ).
  • activator reaction
    Ȱ¼ºÈ­¹ÝÀÀ.
  • acyl-plasminogen streptokinase activator complex
    ¾Æ½Ç-Çø®Áî¹Ì³ë°Õ½ºÆ®·¾ÅäŰ³ªÁ¦È°¼ºÁ¦º¹ÇÕü
  • ganglioside activator protein
    °»±Û¸®¿À»çÀ̵å Ȱ¼º´Ü¹éÁú
  • plasmin activator
    Çö󽺹ÎȰ¼ºÁ¦(¡­üÀàõð¥)
  • plasminogen activator
    ÇöóÁî¹Ì³ë°ÕȰ¼º <¹°Áú>.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activated partial prothrombin time
    Ȱ¼º ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • factor ii(prothrombin)
    Á¦2ÀÎÀÚ(ÇÁ·ÎÆ®·Òºó)
  • partial prothrombin time
    ºÎºÐÇÁ·ÎÆ®·Òºó½Ã°£
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó.
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin complex concentrates
    ÇÁ·ÎÆ®·Òºó º¹ÇÕ ³óÃà(¹°)
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£.
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó ½Ã°£
  • serum prothrombin conversion accelera
    Ç÷ûÇÁ·ÎÆ®·ÒºóÀüȯÃËÁø¼Ò(úìôè¡­ï®üµõµòä
  • activator
    Ȱ¼ºÁ¦(üÀàõð¥), ºÎȰü(Ý·üÀô÷). [Ä¡°ú,»ýÈ­]±â´ÉÀû ¾Ç±³Á¤ÀåÄ¡(ѦÒöîÜäÉÎìïáíûöÇ).
  • activator
    Ȱ¼ºÈ­Á¦(üÀàõûúð¥), ºÎȰü(Ý·üÀô÷). Ä¡°ú,»ýÈ­±â´ÉÀû ¾Ç±³Á¤ÀåÄ¡(ѦÒöîÜäÉÎìïáíûöÇ).
  • activator reaction
    Ȱ¼ºÈ­¹ÝÀÀ.
  • acyl-plasminogen streptokinase activator complex
    ¾Æ½Ç-Çø®Áî¹Ì³ë°Õ½ºÆ®·¾ÅäŰ³ªÁ¦È°¼ºÁ¦º¹ÇÕü
  • enzyme activator
    È¿¼ÒȰ¼ºÁ¦.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activator
    Ȱ¼ºÈ­Á¦(üÀàõûùð¥)
  • activator constant
    Ȱ¼ºÈ­Á¦ Ç×¼ö(üÀàõûùð¥ùöâ¦)
  • catabolite activator protein
    īŸº¼¶óÀÌÆ® Ȱ¼ºÈ­ ´Ü¹éÁú(üÀàõûùÓ±ÛÜòõ)
  • plasminogen activator
    Çö󽺹̳ëÀü Ȱ¼ºÀÚ(üÀàõí­)
  • tissue plasminogen activator
    Á¶Á÷(ðÚòÄ)Çö󽺹̳ëÀü Ȱ¼ºÀÚ (üÀàõí­)
  • precursor of serum prothrombin conversion accelerator
    Ç÷û(úìôè)ÇÁ·ÎÆ®·Òºó Àüȯ°¡¼ÓÁ¦ Àü±¸¹°Áú(ï®üµÊ¥áÜð¥îñÏÌÚªòõ)
  • prothrombin
    ÇÁ·ÎÆ®·Òºó
  • prothrombin derivatives theory
    ÇÁ·ÎÆ®·Òºó À¯µµÃ¼ ÀÌ·Ð(ë¯Óôô÷×âÖå)
  • prothrombin factor
    ÇÁ·ÎÆ®·Òºó ÀÎÀÚ(ì×í­)
  • serum prothrombin conversion accelerator
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÃËÁøÁ¦(ï®üµõµòäð¥)
  • serum prothrombin converting factor
    Ç÷û(úìôè) ÇÁ·ÎÆ®·Òºó ÀüȯÀÎÀÚ(ï®üµì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prothrombin time
    ÇÁ·ÎÆ®·Òºó½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PPCA plasma prothrombin conversion accelerator; proserum prothrombin conversion accelerator
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
APSAC acylated plasminogen-streptokinase activator complex; anisoylated plasminogen streptokinase activato...
PT   1) Prothrombin Time
  2) Physical Therapy; ¹°¸®¿ä¹ý
  3) Pulmonary...
APCD acquired prothrombin complex deficiency [syndrome]; adult polycystic kidney disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DCP Des-gamma-carboxy prothrombin
PCC Prothrombin Complex Concentrates
PT Prothrombin Time
APCC activated prothrombin complex concentrate
APTT activated partial prothrombin time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acyl-plasminogen streptokinase activator complex
    ¾Æ½Ç-Çø®Áî¹Ì³ë°Õ½ºÆ®·¾ÅäŰ³ªÁ¦ Ȱ¼º
  • enzyme activator
    È¿¼Ò Ȱ¼ºÁ¦
  • recombinant plasminogen activator
    ÀçÁ¶ÇÕ Çö󽺹̳ë°Õ Ȱ¼ºÁ¦
  • partial prothrombin time
    ºÎºÐ ÇÁ·ÎÆ®·Òºó ½Ã°£
  • plasma prothrombin time
    Ç÷Àå ÇÁ·ÎÆ®·Òºó ½Ã°£
  • prothrombin consumption test
    ÇÁ·ÎÆ®·Òºó ¼Òºñ ½ÃÇè
    ³»Àμº Æ®·Òº¸ÇÃ¶ó½ºÆ¾ÀÇ Çü¼º·® ÃøÁ¤À» ÁÖµÈ ¸ñÀûÀ¸·Î ÇÏ´Â ½ÃÇèÀ¸·Î, ÀÀÇ÷ ¿Ï·á ÈÄ¿¡ ³²¾Æ ÀÖ´Â Ç÷û ÇÁ·ÎÆ®·ÒºóÀ» ÃøÁ¤ÇÑ´Ù. ÀÌ ½ÃÇèÀº Àüü Ç÷¾×¿¡ ´ëÇÏ¿© ÇàÇϱ⠶§¹®¿¡, Ç÷¼ÒÆÇÀÇ ÀÀÇ÷ ±â´É ÃøÁ¤¿¡ °£Á¢ÀûÀ¸·Î »ç¿ëµÈ´Ù.
  • prothrombin test
    ÇÁ·ÎÆ®·Òºó ½ÃÇè
    ÀÀÇ÷ ½Ã°£¿¡ ±âÃÊÇÑ ÇÁ·ÎÆ®·Òºó °ËÃâ ½ÃÇè.
  • two-stage prothrombin test
    ÀÌ ´Ü°è ÇÁ·ÎÆ®·Òºó ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
proserum prothrombin conversion accelerator A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs.
(12 Dec 1998)
prothrombin Clotting Factor II.
Origin: Gr. Thrombos = cloth in
(18 Nov 1997)
prothrombin accelerator <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
prothrombin and proconvertin test A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs.
Synonym: P and P test.
(05 Mar 2000)
prothrombin deficiency A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs.
Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases.
(27 Sep 1997)
prothrombin test A quantitative test for prothrombin in the blood based on the clotting time of oxalated blood plasma in the presence of thromboplastin and calcium chloride; measures the integrity of the extrinsic and common pathways of coagulation.
See: prothrombin time.
Synonym: Quick's method, Quick's test.
(05 Mar 2000)
prothrombin time Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins.
(12 Dec 1998)
serum prothrombin conversion accelerator <chemical> Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor viia in the extrinsic pathway of blood coagulation. The activated form then catalyses the activation of factor x to factor xa.
Chemical name: Blood-coagulation factor VII
(12 Dec 1998)
activator <biochemistry> A DNA-binding transcription metabolite that positively modulates an allosteric enzyme or regulates one or more genes by increasing the rate of transcription.
(12 Mar 1998)
activator appliances Loose-fitting removable orthodontic appliances which redirect the pressures of the facial and masticatory muscles onto the teeth and their supporting structures to produce improvements in tooth arrangements and occlusal relations.
(12 Dec 1998)
catabolite gene activator catabolite (gene) activator protein
catabolite gene activator protein <molecular biology, protein> A regulatory protein that triggers the transcription of genes that generate the enzymes bacteria need to usenutrients when glucose isabsent.
(16 Mar 1998)
catabolite (gene) activator protein A protein that can be activated by cAMP, whereupon it affects the action of RNA polymerase by binding it with it or near it on the DNA to be transcribed.
Synonym: cAMP receptor protein, catabolite gene activator.
(05 Mar 2000)
plasminogen activator <enzyme> Serine protease that acts on plasminogen to generate plasmin. Has also been implicated in invasiveness and is produced by many normal and invasive cells. The vascular form (tPA, 55 kD) is very similar to tissue plasminogen activator (uPA, 70 kD) and to streptokinase and urokinase.
(18 Nov 1997)
plasminogen activator inhibitor 1 <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator.
Pharmacological action: serine proteinase inhibitors.
(12 Dec 1998)
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
prothrombin activator any of the substances in the intrinsic or extrinsic pathways of coagulation including factors III, VII, X, and XII.
Ãâó: www.merckmedicus.com/pp/us/hcp/thcp_dorlands_conte...
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • activator
    Ȱµ¿ÀûÀÌ µÇ°Ô ÇÏ´Â »ç¶÷;Ȱ¼º¹°;Ȱ¼ºÁ¦;Ȱ¼ºÃ¼
  • prothrombin
    ÇÁ·ÎÆ®·Òºó(ÀÀÇ÷ ÀÎÀÚÀÇ ÀÏÁ¾)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á